Reminder for GRAIL Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Source: Globenewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that GRAIL's defendants made false and misleading statements regarding the NHS-Galleri trial, concealing adverse facts that led to investor losses when the true information became public, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 68.110
Low
38.00
Averages
60.86
High
83.71
Current: 68.110
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for GRAIL Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that GRAIL's defendants made false and misleading statements regarding the NHS-Galleri trial, concealing adverse facts that led to investor losses when the true information became public, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of inflating financial results by pulling forward customer orders during the 2024-2026 period, which undermines investor confidence in the company's future performance and is expected to negatively impact its stock price.
- PicS N.V. Violations: PicS N.V. is alleged to have failed to disclose deficiencies in its credit evaluation procedures during its 2026 IPO, leading to the reclassification of approximately R$590 million in credit exposures and an additional R$88 million expected credit loss, potentially harming its market reputation.
- Verra Mobility Dependency Issues: Verra Mobility Corporation is accused of not disclosing its growth plan's reliance on renewing its contract with Avis, which may render its 2026 performance guidance unattainable, thereby affecting investor confidence.
- Grail, Inc. Misleading Statements: Grail, Inc. is alleged to have been overly optimistic about its clinical trial results from 2025 to 2026, ignoring potential negative trends, which could lead to misjudgments about its future prospects among investors.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws from May 13, 2025, to February 19, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misrepresented the likelihood of achieving a significant reduction in Stage III-IV cancers in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Misleading Research Results: The defendants' optimism regarding the NHS-Galleri study was alleged to lack a reasonable basis, ignoring emerging data trends, rendering their statements about the company's business and operations materially false and misleading throughout the relevant period.
- Investor Action Recommendation: Affected investors have until August 4, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, ensuring no upfront costs for investors wishing to participate in the lawsuit.
See More
GRAIL, Inc. Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc., alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until August 4, 2026, to apply as Lead Plaintiff.
- Stock Price Plunge: Following the announcement that the NHS-Galleri Trial did not observe a statistically significant reduction in Stage III-IV, GRAIL's stock price fell over 50% on February 19, 2026, resulting in significant losses for investors and highlighting a crisis of confidence in the company.
- Legal Consultation Info: Investors are encouraged to contact Pomerantz LLP via email or phone for information on joining the class action, demonstrating the firm's proactive approach to protecting investor rights.
- Historical Context: Pomerantz LLP is a prominent law firm in the field of securities class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, indicating the legal community's serious attention to the GRAIL situation.
See More
Investors Urged to Join Grail Securities Class Action
- Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., particularly for investors who purchased shares between May 13, 2025, and February 19, 2026, urging them to contact the firm before the August 4, 2026 deadline to seek lead plaintiff status.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not meet its primary endpoint, the company's stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements to investors regarding the NHS-Galleri trial's ability to significantly reduce Stage III and IV cancer rates, while concealing that the trial's design and screening duration were likely inadequate to demonstrate this, potentially hiding critical negative information.
- Investor Rights Protection: Faruqi & Faruqi is soliciting information related to Grail's conduct from whistleblowers and former employees to protect investors' rights in the lawsuit, ensuring they can recover their losses through the class action.
See More
Class Action Reminder for Grail, Inc. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026, that a class action has been filed, alleging the company misled investors regarding the success probability of the NHS-Galleri trial.
- Key Allegations: The complaint states that during the class period, Grail, Inc. made false statements about the success rate of the NHS-Galleri trial's primary endpoint, claiming its effectiveness in real-world applications and positive predictive value, leading investors to misunderstand its potential.
- Stock Price Plunge: On February 19, 2026, Grail reported that its
See More
Reminder for GRAIL Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation among affected investors.
- Case Background: The lawsuit alleges that GRAIL's defendants made false and misleading statements regarding the NHS-Galleri trial, concealing adverse facts that led to investor losses when the true information became public, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is accused of inflating financial results by pulling forward customer orders during the 2024-2026 period, which undermines investor confidence in the company's future performance and is expected to negatively impact its stock price.
- PicS N.V. Violations: PicS N.V. is alleged to have failed to disclose deficiencies in its credit evaluation procedures during its 2026 IPO, leading to the reclassification of approximately R$590 million in credit exposures and an additional R$88 million expected credit loss, potentially harming its market reputation.
- Verra Mobility Dependency Issues: Verra Mobility Corporation is accused of not disclosing its growth plan's reliance on renewing its contract with Avis, which may render its 2026 performance guidance unattainable, thereby affecting investor confidence.
- Grail, Inc. Misleading Statements: Grail, Inc. is alleged to have been overly optimistic about its clinical trial results from 2025 to 2026, ignoring potential negative trends, which could lead to misjudgments about its future prospects among investors.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws from May 13, 2025, to February 19, 2026, seeking damages for affected investors.
- False Statements Allegation: The complaint claims that defendants misrepresented the likelihood of achieving a significant reduction in Stage III-IV cancers in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Misleading Research Results: The defendants' optimism regarding the NHS-Galleri study was alleged to lack a reasonable basis, ignoring emerging data trends, rendering their statements about the company's business and operations materially false and misleading throughout the relevant period.
- Investor Action Recommendation: Affected investors have until August 4, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, ensuring no upfront costs for investors wishing to participate in the lawsuit.
See More
GRAIL, Inc. Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc., alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors having until August 4, 2026, to apply as Lead Plaintiff.
- Stock Price Plunge: Following the announcement that the NHS-Galleri Trial did not observe a statistically significant reduction in Stage III-IV, GRAIL's stock price fell over 50% on February 19, 2026, resulting in significant losses for investors and highlighting a crisis of confidence in the company.
- Legal Consultation Info: Investors are encouraged to contact Pomerantz LLP via email or phone for information on joining the class action, demonstrating the firm's proactive approach to protecting investor rights.
- Historical Context: Pomerantz LLP is a prominent law firm in the field of securities class litigation, founded over 85 years ago, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, indicating the legal community's serious attention to the GRAIL situation.
See More
Investors Urged to Join Grail Securities Class Action
- Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., particularly for investors who purchased shares between May 13, 2025, and February 19, 2026, urging them to contact the firm before the August 4, 2026 deadline to seek lead plaintiff status.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not meet its primary endpoint, the company's stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements to investors regarding the NHS-Galleri trial's ability to significantly reduce Stage III and IV cancer rates, while concealing that the trial's design and screening duration were likely inadequate to demonstrate this, potentially hiding critical negative information.
- Investor Rights Protection: Faruqi & Faruqi is soliciting information related to Grail's conduct from whistleblowers and former employees to protect investors' rights in the lawsuit, ensuring they can recover their losses through the class action.
See More
Class Action Reminder for Grail, Inc. Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026, that a class action has been filed, alleging the company misled investors regarding the success probability of the NHS-Galleri trial.
- Key Allegations: The complaint states that during the class period, Grail, Inc. made false statements about the success rate of the NHS-Galleri trial's primary endpoint, claiming its effectiveness in real-world applications and positive predictive value, leading investors to misunderstand its potential.
- Stock Price Plunge: On February 19, 2026, Grail reported that its
See More
